⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 12, 2024Clinical Infectious DiseasesOpen Access

Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with HIV

José Damas Aline Munting Jacques Fellay David Haerry Catia Marzolini Philip Tarr Ana Steffen Dominique L. Braun Marcel Stoeckle Enos Bernasconi Olivier Nawej Tshikung Christoph A. Fux Katharine Darling Charles Béguelin Gilles Wandeler Matthias Cavassini Bernard Surial Irène A. Abela Karoline Aebi‐Popp A Anagnostopoulos Manuel Battegay Enos Bernasconi Dominique L. Braun H C Bucher Alexandra Calmy Matthias Cavassini Angela Ciuffi G Dollenmaier Matthias Egger Luigia Elzi Jan Fehr Jacques Fellay Hansjakob Furrer C A Fux Huldrych F. Günthard Anna Hachfeld David Haerry Barbara Hasse Hans H. Hirsch Matthias Hoffmann Irène Hösli Michael Huber David Jackson‐Perry C R Kahlert Laurent Kaiser Olivia Keiser Thomas Klimkait Roger D. Kouyos Helen Kovari Katharina Kusejko Niklaus Daniel Labhardt Karoline Leuzinger Begoña Martínez de Tejada Catia Marzolini Karin J. Metzner N Müller Johannes Nemeth Dunja Nicca Julia Notter P Paioni Giuseppe Pantaleo Matthieu Perreau Andri Rauch Luisa Salazar‐Vizcaya Patrick Schmid R Speck M Stöckle Philip Tarr Alexandra Trkola Gilles Wandeler Maja Weisser Sabine Yerly

View Full Paper

Ask AI

Bookmark

Share

Abstract

Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). Although weight gain was observed among PWH receiving tenofovir alafenamide (TAF), little is known about the potential reversibility after TAF discontinuation. We evaluated weight and metabolic changes 12 months after TAF discontinuation in the Swiss HIV Cohort Study.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Damas et al. (2024) studied this question.

synapsesocial.com/papers/68e6f5edb6db64358766ff9f https://doi.org/10.1093/cid/ciae189

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015–2017Retrospective Study · 2018 · 100 citations
2Tenofovir alafenamide fumarate use for HIV pre-exposure prophylaxis and weight gain2025
3Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study2024 · 3 citations
4Evaluation of Metabolic Changes in Patients Initiated on Tenofovir Alafenamide Fumarate TherapyCohort Study · 2026
5Renal safety of tenofovir alafenamide-based antiretroviral therapy in people with HIV: A mini-review2024 · 4 citations

Weight Gain on Contemporary Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide in Persons with HIV Starting Antiretroviral Therapy in the United States and Canada2026
To Switch or not to Switch: are there any Antiretroviral Strategies to Attenuate Weight Gain in People with HIV?2026
HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV.2026
Chronic Cardiac Conduit Masses in an Adolescent With a Right Ventricle-to-Pulmonary Artery ConduitClinical Infectious Diseases · 2026
Changing National and Regional Trends in Drug Use-Associated Infective Endocarditis From 2016 to 2022Clinical Infectious Diseases · 2026

More from Clinical Infectious Diseases

More from École Polytechnique Fédérale de Lausanne